Inflammatory Bowel Disease

The pathogenesis of inflammatory bowel disease (IBD) continues to be explored, with the emphasis on genetically determined host immune dysregulation as it applies to interactions with luminal bacteria. The role of endoscopic ultrasound in the evaluation of IBD continues to be studied. Recent advances in the evaluation of enterocutaneous fistulas have been made through the use of hydrogen peroxide to enhance definition of the fistula course and characteristics of the neighboring bowel, as evaluated by transabdominal ultrasound. Refinements have been made in the use and interpretation of the results of surveillance colonoscopy for detection of colorectal cancer and dysplasia in IBD, but a consistent approach still needs to be applied by individual practitioners. New data exist on the usefulness of methotrexate for maintenance of remission, while a lack of efficacy has been demonstrated for mesalamine in the prevention of postoperative recurrence. The role of anti-tumor necrosis factor (TNF) antibody therapy in the treatment of IBD continues to be investigated.

References

• 1 Marteau P. Inflammatory bowel disease.  Endoscopy. 2000;  32 131-137
• 2 Orholm M, Fonager K, Sorensen H. Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease.  Am J Gastroenterol. 1999;  94 3236-3238
• 3 McCartney S, Mitchell J, Fairclough P, et al. Selective COX-2 inhibitors and human inflammatory bowel disease.  Aliment Pharmacol Ther. 1999;  13 1115-1117
• 4 Duchmann R, May E, Heike M, et al. T cell specificity and cross reactivity towards enterobacteria, Bacteroides, Bifidobacterium, and antigens from resident intestinal flora in humans.  Gut. 1999;  44 812-818
• 5 Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the fecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.  Aliment Pharmacol Ther. 1999;  13 1103-1108
• 6 Rembacken B, Snelling A, Hawkey P, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial.  Lancet. 1999;  354 635-639
• 7 Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale?.  Inflamm Bowel Dis. 2000;  6 107-115
• 8 Bernstein C, Blanchard J. Viruses and inflammatory bowel disease: is there evidence for a causal relationship?.  Inflamm Bowel Dis. 2000;  6 34-39
• 9 Kawashima H, Mori T, Kashiwagi Y, et al. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism.  Dig Dis Sci. 2000;  45 723-729
• 10 Pardi D, Tremaine W, Sandborn W, et al. Early measles virus infection is associated with the development of inflammatory bowel disease.  Am J Gastroenterol. 2000;  95 1480-1485
• 11 Korzenik J, Diekgraefe B. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease.  Dig Dis Sci. 2000;  45 1121-1129
• 12 Cucchiara S, Celentano L, de Magistris T, et al. Colonoscopy and technetium-99 m white cell scan in children with suspected inflammatory bowel disease.  J Pediatr. 1999;  135 727-732
• 13 El Maghraoui A, Dougados M, Freneaux E, et al. Concordance between abdominal scintigraphy using technetium- 99m hexamethylpropylene amine oxime-labelled leucocytes and ileocolonoscopy in patients with spondyloarthropathies and without clinical evidence of inflammatory bowel disease.  Rheumatology (Oxford). 1999;  38 543-546
• 14 Maconi G, Parente F, Porro Bianchi G. Hydrogen peroxide enhanced ultrasound-fistulography in the assessment of enterocutaneous fistulas complicating Crohn's disease.  Gut. 1999;  45 874-878
• 15 Maconi G, Ardizzone S, Parente F, et al. Ultrasonography in the evaluation of extension, activity, and follow-up of ulcerative colitis.  Scand J Gastroenterol. 1999;  34 1103-1107
• 16 Soweid A, Chak A, Katz J, et al. Catheter probe-assisted endoluminal US in inflammatory bowel disease.  Gastrointest Endosc. 1999;  50 41-46
• 17 Yang S, Jung H, Kang G, et al. Appendiceal orifice inflammation as a skip lesion in ulcerative colitis: an analysis in relation to medical therapy and disease extent.  Gastrointest Endosc. 1999;  49 743-747
• 18 Kim B, Barnett J, Kleer C, et al. Endoscopic and histological patchiness in treated ulcerative colitis.  Am J Gastroenterol. 1999;  94 3258-3262
• 19 Moum B, Ekbom A, Elgjo K. Change in the extent of colonoscopic and histological involvement in ulcerative colitis.  Am J Gastroenterol. 1999;  94 1564-1569
• 20 Tanaka M, Saito H, Fukuda S, et al. Simple mucosal biopsy criteria differentiating among Crohn disease, ulcerative colitis, and other forms of colitis: measurement of validity.  Scand J Gastroenterol. 2000;  35 281-286
• 21 Carbonnel F, Gargouri D, Lemann M, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis.  Aliment Pharmacol Ther. 2000;  14 273-279
• 22 Bonner G, Petras R, Cheong D, et al. Short- and long-term follow-up of treatment for lymphocytic and collagenous colitis.  Inflamm Bowel Dis. 2000;  6 85-91
• 23 Wandall E, Damkier P, Moller Pedersen F, et al. Survival and incidence of colorectal cancer in patients with ulcerative colitis in Funen county diagnosed between 1973 and 1993.  Scand J Gastroenterol. 2000;  35 312-317
• 24 Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study.  Aliment Pharmacol Ther. 2000;  14 145-153
• 25 Shetty K, Rybicki L, Brzezinski A, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis.  Am J Gastroenterol. 1999;  94 1643-1649
• 26 Walsh S, Murphy M, Silverman M, et al. p27 expression in inflammatory bowel disease-associated neoplasia.  Am J Path. 1999;  155 1511-1518
• 27 Eaden J, Ward B, Mayberry J. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance.  Gastrointest Endosc. 2000;  51 123-128
• 28 Rubin P, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps.  Gastroenterology. 1999;  117 1295-1300
• 29 Engelsgjerd M, Farraye F, Odze R. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis.  Gastroenterology. 1999;  117 1288-1294
• 30 Odze R. Adenomas and adenoma-like DALMs in chronic ulcerative colitis: a clinical, pathological, and molecular review.  Am J Gastroenterol. 1999;  94 1746-1750
• 31 Rubin P. Adenomas in ulcerative colitis: endoscopic polypectomy or colectomy?.  Inflamm Bowel Dis. 1999;  5 304-305
• 32 Petras R. The significance of “adenomas” in ulcerative colitis: deciding when a colectomy should be performed.  Inflamm Bowel Dis. 1999;  5 306-308
• 33 Delco F, Sonnenberg A. A decision analysis of surveillance for colorectal cancer in ulcerative colitis.  Gut. 2000;  46 500-506
• 34 Hunt L, Eichenberger M, Petras R, et al. Use of a microsatellite marker in predicting dysplasia in ulcerative colitis.  Arch Surg. 2000;  135 582-585
• 35 Schramm C, Schirmacher P, Helmreich-Becker I, et al. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis: a case series.  Ann Intern Med. 1999;  131 943-946
• 36 Feagan B, Fedorak R, Irvine E, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease.  N Engl J Med. 2000;  342 1627-1632
• 37 Egan L, Sandborn W, Tremaine W, et al. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis.  Aliment Pharmacol Ther. 1999;  13 1597-1604
• 38 Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity.  Am J Gastroenterol. 2000;  95 1730-1734
• 39 Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.  Gastroenterology. 1999;  117 761-769
• 40 Bell S, Kamm M. Review article: the clinical role of anti-TNF alpha antibody treatment in Crohn's disease.  Aliment Pharmacol Ther. 2000;  14 501-514
• 41 Lochs H, Mayer M, Fleig W, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.  Gastroenterology. 2000;  118 264-273
• 42 D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine.  Gastrointest Endosc. 1999;  50 667-671
• 43 Dubinsky M, Lamothe S, Yang H, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.  Gastroenterology. 2000;  118 705-713
• 44 Korelitz B, Mirsky F, Fleisher M, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.  Am J Gastroenterol. 1999;  94 3248-3253
• 45 Matsuhashi N, Nakajima A, Suzuki A, et al. Long-term outcome of non-surgical strictureplasty using metallic stents for intestinal strictures in Crohn's disease.  Gastrointest Endosc. 2000;  51 343-345
• 46 O'Bichere A, Wilkinson K, Rumbles S, et al. Functional outcomes after restorative panproctocolectomy for ulcerative colitis decreases an otherwise enhanced quality of life.  Br J Surg. 2000;  87 802-807
• 47 Brunel M, Penna C, Tiret E, et al. Restorative proctocolectomy for distal ulcerative colitis.  Gut. 1999;  45 542-545